Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

33.90 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,854
Open 33.90
Bid (Size) 33.93 (1)
Ask (Size) 33.99 (2)
Prev. Close 33.90
Today's Range 33.90 - 33.90
52wk Range 31.77 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 4.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sure Winners: 7 Stocks Set to Outperform in the Next Recession
Are you looking to invest in recession proof stocks? Here are seven stocks set to outperform in the next recession. 
Via InvestorPlace
Topics Economy
Exposures Economy
'Traylor' Effect? Pfizer, Campbell's Soup, Other Brands Are Basking In Travis Kelce-Taylor Swift Romance Rumors
EDO's data reveals that a Pfizer campaign featuring Kelce, which started on Sept. 22, experienced a 32% increase in company-related searches. 
Via Benzinga

Performance

YTD
-33.87%
-33.87%
1 Month
-4.18%
-4.18%
3 Month
-7.02%
-7.02%
6 Month
-17.11%
-17.11%
1 Year
-23.20%
-23.20%

More News

Read More
Novavax Surges After FDA Signs Off On Its Updated Covid Shot, Joining Pfizer, Moderna
Via Investor's Business Daily
Exposures COVID-19 Product Safety
Novavax Stock Soars On FDA Clearance For Updated Covid-19 Shot: What's Going On?
Via Benzinga
Exposures COVID-19 Product Safety
This Is What Whales Are Betting On Pfizer
Via Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:PFE.
Via Chartmill
Is Pfizer Stock a Buy Now?
Via The Motley Fool
The Latest Analyst Ratings for Pfizer
Via Benzinga
AstraZeneca Settles Heartburn Treatment Lawsuit For One Of Biggest Selling Drug
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
Via The Motley Fool
The 3 Top Value Stocks to Watch in Q4 2023
Via InvestorPlace
3 Massively Undervalued Dividend Stocks to Buy for High Total Returns
Via InvestorPlace
Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024
Via InvestorPlace
Is NYSE:PFE a Good Fit for Dividend Investing?
Via Chartmill
Where Will Pfizer Be in 5 Years?
Via The Motley Fool
Is NYSE:PFE suited for dividend investing?
Via Chartmill
3 Top Stocks to Buy in October and Hold Forever
Via The Motley Fool
Nobel Prize Honors Scientists Behind mRNA Vaccines Against Covid-19
Via Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
Via Benzinga
3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street
Via The Motley Fool
Moderna's Shares Could Take Off if These 2 Things Happen
Via The Motley Fool
Why Pfizer and BioNTech Stocks Zoomed Higher Today
Via The Motley Fool
Exposures COVID-19
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Via Benzinga
5 Stocks That Have Massive Upside According to Analysts
Via MarketBeat
After Achieving 100% Cancer Remission Rates In Preclinical Studies, Starpax Magnetodrones Head For Human Trials
Via News Direct
Topics Death
Exposures Death
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.